Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
about
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patientsA comparison of association methods for cytotoxicity mapping in pharmacogenomics.Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.A pharmacogene database enhanced by the 1000 Genomes Project.
P2860
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@ast
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@en
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@nl
type
label
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@ast
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@en
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@nl
prefLabel
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@ast
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@en
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
@nl
P2093
P2860
P1476
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity
@en
P2093
M Eileen Dolan
R Stephanie Huang
P2860
P577
2008-01-01T00:00:00Z